Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7657508rdf:typepubmed:Citationlld:pubmed
pubmed-article:7657508lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:7657508lifeskim:mentionsumls-concept:C0025202lld:lifeskim
pubmed-article:7657508lifeskim:mentionsumls-concept:C0449258lld:lifeskim
pubmed-article:7657508lifeskim:mentionsumls-concept:C0300500lld:lifeskim
pubmed-article:7657508pubmed:issue1-6lld:pubmed
pubmed-article:7657508pubmed:dateCreated1995-10-3lld:pubmed
pubmed-article:7657508pubmed:abstractTextMelanoma often develops from clinically and histologically well-defined precursor lesions. During progression of normal melanocytes to benign nevi, dramatic changes in the expression of adhesion receptors are observed, most notably loss of E-cadherin which mediates adhesion of melanocytes to keratinocytes, and gain of Mel-CAM which predominantly mediates heterotypic adhesion between cells. Major changes in adhesion receptors also occur when cells progress from dysplastic nevi or biologically early radial-growth-phase primary melanomas to biologically late (tumorigenic) vertical-growth-phase primary melanomas. The integrin subunit beta 3 is up-regulated, whereas other integrins such as alpha 6 beta 1 and alpha V beta 1 are down-regulated. This review highlights the major changes in adhesion receptor expression on melanocytes at various stages of tumor progression.lld:pubmed
pubmed-article:7657508pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7657508pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7657508pubmed:languageenglld:pubmed
pubmed-article:7657508pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7657508pubmed:citationSubsetIMlld:pubmed
pubmed-article:7657508pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7657508pubmed:statusMEDLINElld:pubmed
pubmed-article:7657508pubmed:issn0251-1789lld:pubmed
pubmed-article:7657508pubmed:authorpubmed-author:HerlynMMlld:pubmed
pubmed-article:7657508pubmed:authorpubmed-author:NesbitMMlld:pubmed
pubmed-article:7657508pubmed:issnTypePrintlld:pubmed
pubmed-article:7657508pubmed:volume14lld:pubmed
pubmed-article:7657508pubmed:ownerNLMlld:pubmed
pubmed-article:7657508pubmed:authorsCompleteYlld:pubmed
pubmed-article:7657508pubmed:pagination131-46lld:pubmed
pubmed-article:7657508pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:7657508pubmed:meshHeadingpubmed-meshheading:7657508-...lld:pubmed
pubmed-article:7657508pubmed:meshHeadingpubmed-meshheading:7657508-...lld:pubmed
pubmed-article:7657508pubmed:meshHeadingpubmed-meshheading:7657508-...lld:pubmed
pubmed-article:7657508pubmed:meshHeadingpubmed-meshheading:7657508-...lld:pubmed
pubmed-article:7657508pubmed:meshHeadingpubmed-meshheading:7657508-...lld:pubmed
pubmed-article:7657508pubmed:meshHeadingpubmed-meshheading:7657508-...lld:pubmed
pubmed-article:7657508pubmed:meshHeadingpubmed-meshheading:7657508-...lld:pubmed
pubmed-article:7657508pubmed:articleTitleAdhesion receptors in human melanoma progression.lld:pubmed
pubmed-article:7657508pubmed:affiliationWistar Institute, Philadelphia, Pa 19104-4268, USA.lld:pubmed
pubmed-article:7657508pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7657508pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:7657508pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7657508lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7657508lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7657508lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7657508lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7657508lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7657508lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7657508lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7657508lld:pubmed